Menotrophin 75IU, 600IU, 1200IU Injection — Highly Purified FSH + LH for Controlled Ovarian Stimulation in IVF, ICSI and IUI
Menopur® (Menotrophin) — Highly Purified Gonadotropin for Controlled Ovarian Stimulation
The Gold Standard Combined FSH + LH Preparation for IVF and Assisted Reproduction
Menopur® (Menotrophin) is a highly purified preparation of human menotropins containing equal activity of follicle-stimulating hormone (FSH) and luteinising hormone (LH) — used for controlled ovarian stimulation (COS) in women undergoing assisted reproductive technology (ART) including in vitro fertilisation (IVF), intracytoplasmic sperm injection (ICSI), and intrauterine insemination (IUI). Unlike recombinant FSH preparations that contain FSH alone, Menopur provides both FSH and LH activity — more closely mimicking the natural hormonal environment of a stimulated cycle and potentially improving oocyte quality and embryo development.
A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Menopur (Menotrophin) 600IU and 1200IU to hospitals, IVF centres, reproductive medicine clinics, and pharmacies across India. Manufactured by Ferring Pharmaceuticals, a global leader in reproductive medicine, Menopur is one of the most widely used and studied gonadotropin preparations in IVF practice worldwide — backed by over three decades of clinical experience.
What is Menopur (Menotrophin)?
Menopur contains highly purified human menotropins — a preparation of gonadotropins extracted from the urine of postmenopausal women and purified to a high degree through immunoaffinity chromatography. The active substance is described as highly purified human menopausal gonadotropin (HP-hMG) containing equal FSH and LH activity (1:1 ratio) as well as human chorionic gonadotropin (hCG) which contributes to the LH activity.
The two gonadotropins in Menopur work together to stimulate follicular development:
FSH Component:
LH Component:
This combined FSH+LH activity is physiologically meaningful — particularly in GnRH antagonist cycles where LH suppression may be more profound, and in patients with hypogonadotrophic hypogonadism where endogenous LH is absent.
Full prescribing information is available at the Ferring Menopur prescribing information.
Clinical Studies and Evidence
MERIT Trial (Menopur vs Gonal-F in GnRH Antagonist IVF) Published in Reproductive BioMedicine Online (2010), the MERIT trial — a multicentre randomised controlled trial — compared HP-hMG (Menopur) directly to recombinant FSH (Gonal-F) in GnRH antagonist IVF cycles. The trial demonstrated comparable ongoing pregnancy rates between the two preparations — with evidence suggesting a beneficial effect of the LH component in Menopur on oocyte and embryo quality, reflected in fewer oocytes required to achieve a pregnancy in the HP-hMG group.
MEGASET Trial (Menopur vs recFSH in GnRH Antagonist Cycles) Published in Human Reproduction (2015), the MEGASET trial — a large multicentre RCT — demonstrated that HP-hMG (Menopur) achieved a significantly higher live birth rate per started cycle compared to recombinant FSH in GnRH antagonist IVF cycles — 29.8% vs 26.0% — establishing the clinical benefit of combined FSH+LH activity in the most commonly used IVF protocol globally.
Cochrane Review — Urinary vs Recombinant Gonadotropins A Cochrane systematic review of 42 trials comparing urinary and recombinant gonadotropins including HP-hMG found no significant difference in live birth rates overall — but suggested HP-hMG may achieve slightly higher live birth rates in specific subgroups, particularly in GnRH antagonist protocols.
HYPO Trial (Menopur in Hypogonadotrophic Hypogonadism) Studies in women with hypogonadotrophic hypogonadism (WHO Group I anovulation) — where endogenous LH is absent — demonstrate that combined FSH+LH preparations including Menopur are essential for follicular development and ovulation induction, as FSH alone is insufficient without LH activity.
Long-Term Safety Data Decades of post-marketing surveillance and multiple registry studies confirm Menopur’s favourable long-term safety profile in fertility treatment — with no evidence of increased cancer risk or adverse offspring outcomes beyond background rates in the ART population.
Available Strengths
Menopur is available in the following strengths:
| Presentation | FSH Activity | LH Activity | Use |
|---|---|---|---|
| Menopur 75IU | 75IU FSH | 75IU LH | Starting dose / low responders / IUI cycles |
| Menopur 600IU | 600IU FSH | 600IU LH | Standard IVF stimulation |
| Menopur 1200IU | 1200IU FSH | 1200IU LH | Higher dose requirements / fewer vials |
Each vial contains lyophilised HP-hMG powder — reconstituted with the provided solvent (sodium chloride solution) immediately before subcutaneous injection. The 1200IU presentation reduces the number of vials required per cycle — improving convenience for patients requiring higher doses.
Indications — What Menopur is Used For
Controlled Ovarian Stimulation for ART:
Anovulation:
Hypogonadotrophic Hypogonadism:
For detailed indication information refer to MedlinePlus Menotropins.
Key Benefits of Menopur
Combined FSH + LH Activity — Physiological Stimulation Menopur provides equal FSH and LH activity in a single injection — more closely mimicking the natural pituitary gonadotropin output during a stimulated cycle. This is particularly important during GnRH antagonist cycles where LH suppression may be profound and the LH component in Menopur helps maintain adequate androgen production for optimal oocyte development.
Proven Superior Live Birth Rates in GnRH Antagonist Cycles The MEGASET trial — the largest head-to-head IVF trial comparing HP-hMG to recombinant FSH in GnRH antagonist cycles — demonstrates significantly higher live birth rates with Menopur. As GnRH antagonist protocols are now the dominant IVF protocol globally, this data directly supports Menopur as the preferred gonadotropin in contemporary IVF practice.
Better Oocyte and Embryo Quality Multiple studies including the MERIT trial suggest HP-hMG achieves comparable pregnancy rates with fewer oocytes — reflecting improved oocyte quality when combined FSH+LH stimulation is used. This may translate to better embryo development and lower cancellation rates due to poor embryo quality.
Essential in LH-Deficient Patients In women with hypogonadotrophic hypogonadism (absent endogenous LH) — combined FSH+LH therapy is not just preferable but essential. FSH alone cannot achieve adequate follicular development in the absence of LH-driven theca cell androgen production. Menopur provides both components in a single daily injection.
High Purity — Consistent Batch-to-Batch Activity Menopur’s immunoaffinity chromatography purification process ensures highly consistent FSH and LH activity — with minimal batch-to-batch variation in clinical effect. This consistency is important in fertility treatment where precise gonadotropin dosing is essential for optimal stimulation response.
Two High-Dose Presentations — 600IU and 1200IU The availability of both 600IU and 1200IU presentations provides flexibility — the 1200IU presentation significantly reduces the number of vials per cycle for patients requiring higher doses, reducing preparation time and improving convenience.
How Menopur Works
The hypothalamic-pituitary-gonadal (HPG) axis normally controls follicular development through pulsatile GnRH secretion → pulsatile LH and FSH release → follicular growth and ovulation. In IVF, this natural axis is suppressed (by GnRH agonist or antagonist) and replaced by exogenous gonadotropin administration — allowing controlled stimulation of multiple follicles simultaneously.
FSH in Menopur:
LH (and hCG) in Menopur:
Monitoring and Response: Follicular development is monitored by transvaginal ultrasound (follicle size measurement) and blood estradiol levels. Menopur dose is adjusted daily based on ovarian response — aiming for the development of 8-15 dominant follicles (≥14-17mm) before triggering ovulation with hCG or GnRH agonist.
For a detailed overview of gonadotropin use in ART refer to the European Society of Human Reproduction and Embryology (ESHRE) ovarian stimulation guidelines.
Menopur vs Recombinant FSH — Key Differences
| Feature | Menopur (HP-hMG) | Recombinant FSH (Gonal-F, Puregon) |
|---|---|---|
| Source | Purified from postmenopausal urine | Recombinant DNA in CHO cells |
| FSH Activity | ✅ Present | ✅ Present |
| LH Activity | ✅ Present (equal to FSH) | ❌ Absent |
| hCG Activity | ✅ Present | ❌ Absent |
| Best Protocol | GnRH antagonist | GnRH antagonist or agonist |
| Live Birth Rate (MEGASET) | 29.8% | 26.0% |
| LH-deficient patients | ✅ Preferred | ❌ Insufficient alone |
| Batch Consistency | High (immunoaffinity purification) | Very high (recombinant) |
| Available at A.K. Pharma | Request Quote | Contact us |
Dosage and Administration
Controlled Ovarian Stimulation for IVF:
Anovulation (IUI cycles):
Hypogonadotrophic Hypogonadism:
Reconstitution Instructions:
Full dosing guidelines available at Drugs.com Menotropins Dosage.
Monitoring During Menopur Treatment
Close monitoring is essential throughout stimulation to optimise response and prevent ovarian hyperstimulation syndrome (OHSS):
OHSS Risk Reduction:
Who Should Use Menopur
Menopur is prescribed for:
Menopur is prescribed by reproductive endocrinologists, gynaecologists, and fertility specialists at IVF centres. A.K. Pharma supplies Menopur to IVF centres, hospitals, and pharmacies across Delhi and India.
Possible Side Effects
Common side effects include injection site reactions (pain, bruising, redness), headache, pelvic discomfort, ovarian cysts, and nausea.
The most important serious side effect is:
Full side effect information available at MedlinePlus Menotropins Safety.
Precautions and Contraindications
Menopur is contraindicated in:
Additional precautions:
Storage and Handling
As a responsible medicine distributor in Delhi, A.K. Pharma stores all medicines including Menopur under manufacturer-recommended conditions ensuring product integrity for every supply to IVF centres and clinics.
Manufacturer Information
Menopur (Menotrophin) is manufactured by Ferring Pharmaceuticals, a privately held global biopharmaceutical company with a unique focus on reproductive medicine and maternal health. Ferring has been developing and manufacturing gonadotropins for fertility treatment for over 50 years — with Menopur being their flagship product in reproductive medicine. A.K. Pharma supplies only genuine Menopur sourced from authorized Ferring distributors.
Related Hormone and Fertility Medicines Available at A.K. Pharma
Frequently Asked Questions
Q. What is Menopur used for? Menopur (Menotrophin) is used for controlled ovarian stimulation in women undergoing IVF, ICSI, and IUI fertility treatments, and for ovulation induction in women with anovulation. More information available at MedlinePlus.
Q. What is the generic name of Menopur? The generic name of Menopur is Menotrophin (or Menotropins). It is a highly purified preparation of human menopausal gonadotropins containing equal FSH and LH activity.
Q. What is the difference between Menopur 600IU and 1200IU? Both contain the same HP-hMG active ingredient with equal FSH and LH activity. The 1200IU presentation simply contains twice the dose in a single vial — reducing the number of vials required per stimulation cycle for patients needing higher doses. Both are used in exactly the same way clinically.
Q. How is Menopur different from Gonal-F (recombinant FSH)? Menopur contains both FSH and LH activity while Gonal-F contains FSH only. The MEGASET trial demonstrated significantly higher live birth rates with Menopur vs Gonal-F in GnRH antagonist IVF cycles — likely due to the LH component in Menopur optimising theca cell androgen production and oocyte quality.
Q. What is OHSS and how is it prevented with Menopur? Ovarian Hyperstimulation Syndrome (OHSS) is an excessive ovarian response to gonadotropin stimulation — ranging from mild discomfort to potentially life-threatening complications. OHSS is prevented by careful dose titration based on daily monitoring with transvaginal ultrasound and estradiol levels, prompt dose reduction if excessive response develops, and using GnRH agonist trigger instead of hCG in high-risk patients.
Q. Is Menopur available in India? Menopur can be supplied to IVF centres, hospitals, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.
Q. What is the price of Menopur in India? Menopur price in India varies by strength and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Menopur from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Menopur in bulk? Yes. A.K. Pharma supplies Menopur in bulk to IVF centres, reproductive medicine clinics, hospitals, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.
Q. Where can I find clinical evidence for Menopur? Key Menopur clinical trials including MERIT and MEGASET are published in Reproductive BioMedicine Online and Human Reproduction. Gonadotropin guidelines are available from ESHRE.
Why Order Menopur from A.K. Pharma?
Contact A.K. Pharma for Menopur Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in
